In this study, we report the generation of a novel C21/7D12 bispecific VHH and use in vitro and ex vivo studies using patient PBMC and colorectal cancer samples to demonstrate that this bispecific VHH can induce a strong NK cell effector response of both autologous and allogeneic NK cells against EGFR-expressing tumors independent of tumor RAS mutation status. Here, EGFR is linked to neoplasm.